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1. Introduction 
  
Clinical characteristics of glioblastoma 
The term glioblastoma first appeared in the scientific literature based on joint works by Bailey 
and Cushing in 1926. It was assumed that glioblastoma develops from glial cells or 
their progenitors. Originally,  “glioblastoma multiforme” was the official terminology, 
referring to the extraordinary inter- and intratumor heterogeneity of the tumor. Since the 
WHO's classification of gliomas in 2007, it is designated as glioblastoma, and abbreviated as 
"gbm". Symptoms of the disease have a high degree of variability, depending on which brain 
regions are affected by the cancer, what the biological characteristics are, how advanced the 
condition is and what physical condition the patient enjoys. Certainsymptoms such as 
epileptic seizures, headaches, nausea, vomiting, nosebleeds, etc. are associated with increased 
volume of the tumor. The general symptoms may worsen over time and focal  neurological 
signs (speech disturbances, weakness of the arm and leg, cognitive decline, and personality 
changes) may also develop according to the affected brain area.  Glioblastoma may develop in  
any parts of the central nervous system. It most often affects, however, the hemisferium, the 
frontal lobes in particular. It is somewhat less likely to develop in the temporal, parietal and 
occipital lobes, in this order of frequency. 
In contrast to the typical appearance of adult glioblastomas, a study by Gusnard et al ( 1990) 
highlighted that pediatric glioblastomas are typically localized in the brain stem and 
cerebellar regions.  
Glioblastoma is the most frequently occurring primary malignant brain tumor in adults. The 
median survival remains just a little over a year, while the five-year survival rate is 5%  with 
complete surgical resection, radiation and chemotherapy.  Publication of the Stupp protocol in 
2005 was a significant step forward. This protocol recommending  surgical removal of 
the tumor with wide margins, and then combined  radiation therapy with temozolomide 
chemotherapy increased progression-free survival time of patients. The median survival of 
12.3 months increased to 14.6 months, and the two-year survival increased from 12 to 26 
percent. 
While a number of molecular-based experimental therapies are currently being developed  or 
tested in the preclinical setting, the  only approved therapy is based on the Stupp protocol  
world-wide, including Hungary . 
  
The histological characteristics of glioblastoma 
The WHO proposed classification of gliomas according to their histological properties into 
four grades (I-IV, where I is the least, IV is the most malignant) in 2007. Glioblastoma is a 
grade IV glioma. Glioblastoma is characterized by a high level of inter- and intratumor 
heterogeneity, that reflects not only cytomorphological heterogeneity, but also a varying 
mixture of mesenchymal and primitive neuroectodermal elements with tumor cells of glial 
origin. According to refined histological features, Burger and his colleagues sorted  
glioblastomas into eight subgroups in 1987. 
A histological hallmark of glioblastomas includes invasiveness, meaning that the tumor cells 
invade into the normal brain tissue, so the actual tumor has often larger size than  it appears 
on MRI. Further, the tumor is characterized by pleomorphism, cellularity, vascularization and 
necrosis. Because of  the angioneogenesis, abnormal blood-vessels grow with impaired blood-
brain barrier within the glioblastoma tumors, where immune cells may enter. Berghoff and his 
collegues (2014), Bottino and his collegues (2014), and Navarro and his his collegues (2014) 
analyzed in several ways as to how the immune infiltration influences patients’ survival, 
however, without unequivocal results. The anaplastic tumor cells stuck 
in different stages of differentiation, which can be seen in the histological images. 
The tumor also includes glioblastoma stem cells that are likely to contribute to  its growth and 
recidive formation properties as well as its drug- and radiation resistance. 
Glioblastoma may be primary (de novo transformation of normal glial cells ), or secondary in 
origin (a lower gradient glioma is transformed into glioblastoma). The secondary 
glioblastoma generally has a better prognosis when patients are typically younger (under 50 
years) and have longer survival in conjunction with specific molecular genetic profiles 
of the tumor. 
  
Metabolic characteristics of glioblastomas 
The growth of the tumor leads to hypoxia in the central, less vascularized parts, where 
consequently necrosis frequently develops.  In order to enhance its blood supply, the tumor 
induces angiogenesis in its microenvironment via the activation  specific genes and 
molecules. Such molecules include  the hypoxia inducible factor 1 (HIF-1), tumor necrosis 
factor alpha (TNF-α), zinc finger protein 39 (ZNF39) the Abelson Interactor family  member 
3 (ABI3),  the ABI3 binding-interacting protein 3 (AIP3) and   the Triggering Receptor 
Expressed on  myeloid cells 1 (TREM1).  A study by Nagy and his colleagues 
(2014)  surveyed altered expression patterns of regulatory genes associated with hypoxia 
which greatly contribute to oxidative glycolysis typical of glioblastoma. 
However, somatic mutations accumulating in cancer also appear to play important roles in the 
development of its metabolic disorders. Many of these mutations  localized to mitochondrial 
DNA or nuclear genes of mitochondrial proteins shift the metabolic pathways in the direction 
of oxidative glycolysis. Several  mitochondrial somatic mutations affect the cytochrome C 
oxidase enzyme. Griguer et al (2013) observed that those who carry such cytochrome C 
mutations in their tumor may face  worse prognosis. 
Mutations affecting the isocitrate dehydro-lipoxygenase  -1 and 2 (IDH-1, IDH-2) enzymes 
are particularly characteristic of glioblastomas. The most frequent of IDH-1  mutation is the 
R132H kodon mutation. The IDH-1 R132H mutant enzyme is functionally impaired, and 
tthus instead of its  normal product,  alpha-ketoglutaratean  onkometabolite called 2-D-
hydroxy glutarate is formed.. Mutations in IDH-2 and 3 also lead to the accumulation of 2-D-
hydroxyglutarate. 2-D-hydroxyglutarate competitively inhibits a number of alpha-
ketoglutarate-dependent molecular processes, which  leads, among other things, to extensive 
changes in epigenetic regulation and gene expression patterns. 
Other key mutations contributing to metabolic changes in the tumor are those affecting the 
pyruvate kinase (PK) and pyruvate dehydrogenase kinase (PDK) enzymes.  Due to mutations 
in the PK enzyme, the process of glycolysis considerably slows down, and many intermediate 
products accumulate. These changes promote proliferation of tumor cells, and alter nucleotide 
and amino acid synthesis. Mutations in the PDK enzymes are associated with  hypoxia, and 
PDK – hypoxia-activated genes mutually regulate each other.  PDK  mutations also shoft the 
metabolic processes  in the direction of oxidative glycolysis. 
  
Molecular Genetic Characteristics of Glioblastoma 
As  all tumors, glioblastoma is characterized by a sequential accumulation of somatic 
mutations, some of which have particular importance in differentiating its biological 
subgroups. One of these mutations is the above mentioned IDH-1 1R132H mutation. Since 
the 2014 revision of the WHO glioma classification , determination of the IDH mutational 
status is the first (and only recommended) molecular test for glioblastomas . Hierarchical 
cluster analyses of OMICS data by The Cancer Genome Atlas (TCGA) Network defined four 
overlapping molecular subgroups of glioblastomas,   including the classic, 
mesenchymal,  neural and proneural subgroups. The  proneural subgroup is characterized 
by IDH-1 mutations, most frequently by the the IDH-1 R132H mutation. The classic subgroup 
is characterized by abnormalities in the Epidermal Growth Factor 
Receptor (EGFR) gene, including EGFR amplification and high expression, as well as the 
presence of the EGFRvIII (from exon II to VII) deletion mutant . EGFRvIII is a constitutively 
active receptor that transmits signal without binding of its ligand, leading to increased cell 
proliferation and reduced apoptotic processes.  Somatic mutations in  tumor suppressors 
genes also play an important role in defining the molecular profiles and subgroups of 
glioblastomas. The mesenchymal subgroup is related to somatic mutations in the NF-
1 (neurofibromin)  gene  or deletions within 17q11.2 encoding this gene. Interestingly, 
germline mutations within NF-1 are also well known in neurological literature, which are 
inherited in an autosomal dominant manner and lead to the development of the 
complex disease, neurofibromatosis-1. Due to mutations in the NF-1 gene, the protein product 
neurofibromin is unable to exert its normal tumor suppressor effects namely the negative 
regulation of  the Ras / MAPK signaling pathway. The lack of or the impairment of this tumor 
suppressor function lead to enhanced tumor cell proliferation and survival. 
  
2. Hypotheses and Objectives 
  
Taking into consideration results of glioblastoma basic research studies, and their insufficient 
clinical translation, we generated the following hypotheses and specific aims:   
 
hypotheses 
In this study we postulated that:  
  
- The molecular subgroups determined by OMICS approaches in frozen glioblastoma 
specimens  by the TCGA may be reproduced by testing selected markers and by methods 
available in routine molecular pathology labs in clinical, formalin-fixed paraffin-embedded 
specimens.. 
  
- The molecular glioblastoma subgroups segregated based on the molecular markers reflect 
biological heterogeneity of the tumor and correlate with clinical outcomes.  
  
-  Glioblastoma tumors largely retain their molecular subgroup classification over time, 
however, signs of further clonal evolution may also be detected. 
  
objectives 
In order to test the above assumptions, we specifically aim to  
  
- Investigate the most important subgroup defining TCGA markers by methods of 
immunohistochemistry (IHC) and pyrosequencing in FFPE glioblastoma specimens that were 
collected in the Pathology Department at the Markusovszky University Teaching Hsopital 
(MUTH) and to test the segregation of subgroups based on the marker profiles.   
- Correlate the patients’ clinical data (age, gender, overall survival) with these molecular 
subgroups.  
  
- Analyze the changes in molecular profiles of those patients from whom more than one 
sequential glioblastoma specimens were available.  
  
 
 
 
 
3. Materials and methods 
patients 
For our studies, 127 FFPE glioblastoma blocks were selected from 112 patients obtained 
between 2000 and 2016 in the Pathology Department, MUTH. Based on the quality and 
quantity of samples, 114 samples from 104 patients were included in the study. Diagnosis of 
glioblastoma was  definite based on clinical and histological studies. 
The patients were divided into two cohorts material. The first cohort included single specimen 
from each patient. These samples were surgically obtained after the diagnosis was established, 
but before chemotherapy and radiotherapy. The second cohort included two or more 
sequential specimens from patients whose tumors were available from the first surgery 
(before radiation and chemotherapy) and after recurrence (after radiation and 
chemotherapy). The 96 glioblastoma specimens from  96 patients in the first cohort were 
examined by our selected molecular markers to test segregation of the glioblastoma 
subgroups. he 18 glioblastoma specimens from 8 patients in the second cohortwere used to 
test the temporal evolution of the molecular tumor profiles.. The majority of the studied 
patients had primary glioblastoma (101), but there were also 3 secondary glioblastoma 
specimens from patients included in the study. 
In the first cohort  46 patients  (44.23%) were men and 58 were women (55.76%). The age of 
patients ranged from 26 to 88 years, their mean age was 61.01 years and their median age was 
63.5 years. The age of men ranged from 26 to 77 years, their average age was 58.89 years, 
their median age was 60 years. The age of women ranged from 32 to 88 years, their average 
age was 61.69, their median age was 65 years. 
  
immunohistochemistry 
Immunohistochemistry tests were optimized for each primary antibody in a preliminary 
study. Regions of interest were selected on the first slides of specimens  in order to examine 
consistent and comparable regions in the future. For this purpose a hematoxylin-eosin staining 
and anti-glial fibrillary acidic  glycoprotein (GFAP) immunostaining were used. Our criteria 
were the following: the selected tissue region had to be malignant  with increased cellular 
density, pleomorphism, and mitosis, which showed GFAP positivity. The proportion of 
necrotic areas was maximized within the evaluation areas at 20%, and the rate of vascularity  
was no more than 25%. The ROI selection was performed under 1:20 and 1:200 magnification 
and selected areas were labeled on each slide. Thus, the IHC analyses with 8 primary 
antibodies were performed on 8 sequential slides, each containing the same ROI (the same 
ROI could be confirmed within 8x3 μm). The primary antibodies were as follows: anti-GFAP, 
anti-NF-1, anti-EGFR, anti-EGFRvIII, anti-P53, anti-ATRX, anti-IDH-1R132H, and anti-
CD133. The secondary antibody and the Diamino-benzidin-based visualization system were 
part of the Novolink Polymer Detection System RE-7140-K (Leica Biosystems, Newcastle, 
United Kingdom).  . The IHC tests were evaluated both manually and 
digitally. Digitalizedquantitation was performed for nuclear and membrane staining (EGFR, 
EGFRvIII, p53) at 100X magnification. The completed digital photos were saved on a DVD 
from the central server of the Pathology Department, at the Tatabanya St. Borbala 
Hospital. Evaluation of the scanned disks was performed by  a 3DHISTECH Pannoramic 
Viewer  1:15 program, complemented by a QuantCenter module ((3D HisTech Kft. 
Budapest, Hungary). The QuanCenter module allows to determine at a selected magnification 
the intensity of cell membrane and / or nuclear staining and percentage of stained cells. By the 
computer, the staining intensity of cells  was rated as 0, +, ++ and +++, while from the stained 
cell counts  the rate of positive cells was determined. The digital evaluation was used to 
confirm and to refine the results obtained by manual evaluation within the ROI areas in case 
of  the three antibodies . We performed manual evaluations of  ROI areas  when IHC 
for  EGFR, p53, NF-1, CD133, ATRX, EGFRvIII, and IDH-1 also R132H were carried 
out. The evaluations were performed by three separate individuals at 1: 200 magnification on 
an Olympus BX51 microscope (Olympus Corp. Japan). For the manual evaluation of EGFR, 
p53, CD133 and ATRX IHC, the staining intensity, similar to that of the computer analysis, 
was manually designated as 0, +, ++ and +++. Three-three fields of view were studied, and 
altogether 100-100 cells were read. In addition to the intensity evaluation, the percentage of 
stained cells was determined. The Histoscore value was obtained by multiplying 
the percentage of positive cells by the staining intensity . The Histoscore value thus had to fall 
between 0 and 300. In case of NF-1 (typically cytoplasmic, but also nuclear and cytoplasmic 
staining), a similar procedure was followed, and the Histoscore was determined  by 
multiplying the IHC staining intensity and percentage of stained cells. However, for the final 
evaluation of NF-1, four staining categories were distinguished: 1. cytoplasmic positivity, 2. 
cytoplasmic and nuclear positivity, 3. nuclear positivity, and 4. cytoplasmic and nuclear 
negativity. In case of two mutation-specific antibodies,  the antiEGFRvIII and anti-IDH-1 
R132H, the presence or absence of  staining (mutation)  were documented, wherein the 
positivity was defined as "++" or "+++" IHC staining intensity  (see above ). 
  
Pyrosequencing 
The IHC results with the anti-IDH-1 R132H antibody were confirmed by pyro-
sequencing. We planned this validation of the IHC results by pyrosequencing for all samples 
positive by IDH-1 R132H IHC and by including two negative controls. In addition, we 
planned to pyrosequence all those samples where the anti-IDH-1 R132H IHC did not give 
unambiguous result.  Slides were prepared from the selected blocks and subjected to 
deparaffination using the QiaGen Deparaffinization Solution for FFPE samples 
kit. Subsequently, DNA was purified from the deparaffinated material by the QiaGen® 
QIAamp DNA FFPE Tissue Kit. The concentration values of the DNA samples were 
determined by using the Thermo Scientific® NanoDrop 2000 and the NanoDrop2000 / 2000c 
software package.  The sequences of the PCR and sequencing primers were obtained from a 
publication by Setty et al (2010).. The reverse PCR primer was biotinylated. PCR was 
performed on a BOECO Thermal Cycler SQ BOE8085240 in 40 cycles. The PCR products 
were confirmed by agarose gel electrophoresis. The biotinylated PCR amplicon was purified 
by immobilization, and the presence of IDH-1 R132H mutation was investigated by 
pyrosequencing on an automatic device detailed  in the preliminary studies .  
  
statistical methods 
Once the results of IHC were confirmed and finalized, statistical analyzes were carried out in 
several steps first in cohort 1, then in cohort 2.. In the 96 samples of cohort 1:  1. we 
examined manually the  separation of patients / samples based on the IHC markers. 2. 
Hierarchical cluster analyses were performed using SPSS23 to test and confirm the separation 
of molecular subgroups. Results of NF-1, IDH-1 R132H and EGFRvIII IHC were evaluated 
in a nominal +/- based assessment, while for the other IHC markers Histoscore values served 
for the basis of statistical testing. Trees of cluster analyses displayed negative and positive 
data groups as 0 and 1, along with the p-values showing statistical differences . Finally, we 
examined the correlation of clinical parameters (gender, age, overall survival) with the 
molecular subgroups. For gender distribution, we used the Pearson χ
2
 - probe. The age of the 
patients showed no normal distribution, therefore, the Kruskal-Wallis test (multiple groups 
comparable) was used, while the subgroups were compared to the whole patient population by 
using the Mann-Whitney test. The correlation between patient survival and molecular 
subgroups was examined by the Cox regression analysis. In cohort 2,  18 samples of 8 
patients  were evaluated for  molecular classification, and the changes in the molecular 
profiles  were examined in the sequential samples. 
  
4. Results 
  
Preliminary evaluations 
Reviewing data in cohort 1,  we can draw some conclusions prior to the statistical 
analyses. Among all markers examined, three antibodies appeared of key importance in 
segregating  patients / samples into into three subgroups of glioblastoma. These three 
subgroups include   the EGFR - EGFRvIII-positive group, the NF-1 completely (nucleus and 
cytoplasm)  negative group and the IDH-1 R132H positive group. These subgroups (based on  
the marker molecules) likely overlap with the TCGA subgroups: 1) IDH-1 R132H positivity 
(Verhaak et al, 2010, proneural subgroup), 2) EGFR and EGFRvIII combined positivity 
(Verhaak et al, 2010, classic sub-group) and 3 ) NF-1 double negativity (Verhaak et al., 2010, 
mesenchymal subgroup). According to our results, the largest group carries the EGFRvIII 
mutation, and includes 34 patients. Twenty patients showed loss of NF-1 expression in their 
tumors and 10 patients carried IDH-1R132H mutations. Altogether, classification into one of 
three molecular subgroups could be given for  64 patients / specimens out of our 96 patients / 
specimens, also paralleling the TCGA subgroup distribution.  While the subgroup positive for 
the IDH-1 R132H marker completely separated from the other subgroups, the other two 
subgroups showed a slight overlap: a simultaneous detection of EGFRvIII mutation and the 
absence of NF-1 expression were seen in two patients / samples in cohort 1. These results 
indicate in agreement with the TCGA data, that the separation of the glioblastoma subgroups 
based on molecular markers is cluster-like, but not complete.  
  
Detailed  IHC and clinical correlation data of the first cohort 
Ten out of 96 patients  were positivefor the  IDH-1 R132H mutation by IHC. This figure 
represents approximately 10% of our cohort, in consensus with the TCGA proneural subgroup 
representation . Comparing the gender of the patients,there are 46 woman and 40 men (86 
individuals) in the IDH-1 R132H negative subgroup. In the IDH-1 R132H positive subgroup 
7 women and 3 men (10 individuals) can be observed. We could not detect any relationship 
between  gender and the presence of the IDH-1 mutation (χ
2
 test,  95% confidence level 
p= 0.34). 
The age of the patients was also compared within the positive and negative groups. The 
average age of individualsin the IDH-1 positive group (with the R132H mutation)was 56 
years, while in the negative group  it was 62 years. Similarly, there appeared to be a 
difference between median age of the positive and negative subgroups (52.5 years in positive 
and 56 in negative subgroup). However, when the relationship between age and IDH-1 
R132H mutation was testedby the Mann-Whitney test no difference could be detected 
between the positive and negative groups, due to the small size of the mutation positive 
cohort (95% confidence level, p = 0.234). Nevertheless, it is worth of noting that a strong 
trend appeared indicating that patients in the IDH-1 R132H positive group were younger than 
those in the negative group. In the third round, patients’ survival data were  correlated with 
the presence of the IDH-1 R132H mutation. We could access survival data of  9 (90%) 
patients in the mutation positive group, and 59 (69%) patients of the negative group. Overall 
survival was defined as the time interval between the date of surgery and the date of death o, 
given in weeks. In the IDH-1 R132H positive group, the average survival was 82 weeks, 
while the median survival was 24 weeks. In the IDH-1 R132H negative group, the average 
and median survivals were 43 weeks and 26 weeks, respectively. Although there is no 
significant difference here either, the mean values indicate that patients in IDH mutation 
group were younger than patients in the other subgroups (negative group). 
In the second round, expression profiles of NF-1  were correlated with the clinical data. We 
observed four staining patterns: nuclear and cytoplasmic double positive (+ / +), nuclear and 
cytoplasmic double  negativity (- / -), nuclear positive and cytoplasmic negative (n + / c -) and 
nuclear negative and cytoplasmic positive (n - / c +). the pattern observed in the latter case (n- 
/ + c) corresponds typically to the  normal physiological condition .  We compared age, 
gender and survival data of the NF-1 double negative group with those of the n- / c+ group. 
Altogether, there were IHC and survival data available for forty individuals. The gender 
breakdown was as  follows: 20 women and 20 men. The NF-1 double negative  group had 
9 women and 11 men. The n- / c+  group had 11 women and 9 men. The gender distribution 
did not show correlation with the NF-1 expression profile in this comparison (double negative 
vs. n- / c+) (χ
2
 test, 95% confidence level, p = 0.40). The age distributions in the NF-1 
subgroups were similar to that in the IDH-1  subgroup. The average age of surgery was 65 
years for the NF-1 double negative patients, compared to 61.5 years for the n- / c+ patients , 
while the median age was  67 years in the NF-1 double negative group while 62.5 years in the 
NF-1 n- / c+ group   (Mann-Whitney test, 95% confidence level p = 0.22). As to the overall 
survival figures,  the average survival was 56 weeks in NF-1 double negative group, and 49 
weeks in the n- / c+ group. Similarly, the median survival of the double negative group was 
21 weeks, while that of the the n- / c+ group was 11 weeks. 
 
In the third round,  the EGFRvIII positive and negative cohorts were compered for  
clinical outcomes. Of the 96 samples, 34 were positive, and 62 were negative. The EGFRvIII 
mutants typically also showed increased expression of the EGFR protein. This subgroup with 
EGFR overexpression and EGFRvIII mutation likely  overlaps with the TCGA classic 
subgroup. There were 19 women and 15 men in the EGFRvIII positive group, and 35 women 
and t 27 men in the negative group (χ
2
 test, 95% confidence level, p= 0.95).  The  age at 
glioblastoma surgery in the EGFRvIII positive group was 60 years, median 61 years, in the 
negative group these numbers were 62 year and 65 years, respectively (Mann-Whitney test, , 
95% confidence level,  p = 0.74). We could retrieve the patient survival data for 22 
individuals in the EGFRvIII positive group, and for 43 patients in the negative group, giving a 
total  of 65 patients (67.70%). As expected, the overall survival data in these subgroups are 
similar to those of the total cohort,  with  50 weeks of mean survival in the positive vs. 45 
weeks in the negative group, and 22 weeks of median survival in the positive group vs.  26 
weeks of median survival in the negative group. 
  
Finally,  we also performed clinical correlation analyzes in the three molecular glioblastoma 
subgroups. 
Out of the 96 patients, we could obtain overall survival data for 68 patients (~ 71%)  .  The 
Cox regression analysis was performed to determine whether or not patients in the three 
molecular subgroups have different overall survivals  (95% confidence level,  
p= 0.386). Based on this nalysis, there is no difference in the survival data of the three 
outlined molecular subgroups. However, because of the small sample size and the observed 
trends, some careful conclusions may be drawn. The longest survival was noted in the 
subgroup carrying the IDH-1 R132H mutation, while the shortest survival was found in 
subgroup with the loss of NF-1 expression (double negative subgroup). 
  
Cluster analysis 
 Separation of the glioblastoma molecular subgroups was tested by hierarchical cluster 
analyses in cohort 1. The results were presented in a tree diagram. Many possible trees were 
generated, among which we found one that was statistically most significant and biologically 
most plausible.  
In this tree, the presence or absence of IDH-1 R132D mutation separates the glioblastoma 
subgroups  (in agreement with the most recent revision of WHO glioma classification  as 
reported by Louis et al, 2016 ) ( 95% confidence level,  p = 0.001 ). The IDH-1 mutant group  
completely separates  from the others. In the second step, the IDH-1 R132H negative group 
was further analyzed based on the EGFRvIII mutation status. In this step, the EGFRvIII 
positive and negative subgroups also significantly separate from each other ( 95% confidence 
level,  p = 0.022 ). In the final step, the group EGFRvIII negative subgroup was further tested 
according to the NF-1 expression status. Here, the separation of the NF-1 double negative (n-
/c-) group from the other three subgroups (NF-1 + / +, NF-1 +/- and NF-1 -/+ ) could be 
observed ( 95% confidence level,  p = 0.059 ), although did not quite reach statistical 
significance.  Given that the observed p-value is close to the  significance limit, it is possible 
that the  diminished subcohort size in the multi-step analysis is responsible for the lack of 
significance. 
The alternative hierarchical trees were statistically weaker and biologically less plausible than 
the one detailed above.  
Evaluation of the second cohort 
In the second cohort (18 FFPE blocks  from 8 patients; 2 or more surgically removed 
specimens from each), we investigated changes in the IHC-defined molecular patterns over 
time. No profound changes were observed in the molecular patterns of the sequential samples, 
however, certain trends were noted. First, the IDH-1 status was analyzed. None of the tumors 
from the eight patients in this cohort carried the IDH-1 R132H mutation. In the second round, 
we analyzed the NF-1 expression status.  t Change was observed only in patient number 4, 
where no anti-NF-1 staining appeared in the first tumor, but the nucleus was positive in the 
recurrent tumor. Evaluation of the EGFR IHC results was based on the  
Histoscore values (staining intensity  multiplied by the percentage of positive cells). Recurrent 
tumors either showed about the same or somewhat higher EGFR Histoscore values as the first 
surgically removed tumors, an observation compatible with those in other reports.  Presence 
of the EGFRvIII mutation  was detected in the majority of cohort 2, a likely by chance result 
due to the small smaple size. The EGFRvIII status has not changed when the first and 
recurrent tumors were compared. The anti-ATRX  antibody staining pattern, however, was  
just the opposite of the previous staining patterns, as the initially positive ATRX status 
became negative in several of the recurrent tumors.  In  case of the p53 and CD133 IHC,  no 
change could be observed comparing the first and recurrent tumors.  
  
5. Discussion 
  
Based on our results, we conclude that identifying molecular subtypes of glioblastoma is 
feasible by testing the TCGA-OMICS subgroup-defining markers in clinical FFPE 
specimens. Based on the shared markers, a close overlap in the molecular subgroups 
(proneural, classic and mesenchymal) is very likely in our IHC-based and the TCGA OMICS-
based studies,.. Our results not only reproduce the separation of molecular subgroups in 
clinical glioblastoma samples, but the percentage distribution of these molecular subgroups is 
also similar to that reported by the TCGA network. In our study, the patients’ gender did not 
show a differential distribution in the molecular glioblastoma subgroups, and did not show 
any relationship with the onset age or the overall survival of the disease. However, it is worth 
of noting that patients with the IDH-1 R132H mutation in their tumors appeared to be younger 
and had longer survival than those without this mutation, a strong trend in consensus with the 
TCGA dataAnalyses of data in the second cohort, though without statistical testing, show that 
the main subgroup-defining molecular characteristics are retained in sequential glioblastoma 
samples, although  limited changes may be noted even with these few markers which suggest 
that some clonal evolution occurs over time. Our observations are consistent with the 2016 
revision of the WHO glioma classificationthat proposes the integration of the molecular 
markers into the histopathology-based  classification, as well as the separation of 
glioblastomas based on their IDH mutation status into negative and positive subgroups. Of 
note, the IDH-1 R132H positive / negative status also significantly (though not 
entirely) differentiates  primary and secondary glioblastoma tumors. While the 2016 revision 
of the WHO glioma classification did not propose the use of additional  markers for  further 
separation of glioblastoma molecular subgroups, our results suggest that using the 
complementary key markers for separating the major molecular subgroups is not only 
feasible, but is also useful to support clinical decision-making. 
 
As to  the four NF-1 staining patterns,  a number of underlying  molecular events may be 
considered. Such events may include altered gene expression patterns, deletion of epitopes 
recognized by the primary antibody in IHC,  or the  altered intracellular localization of the 
protein. Further research is needed to specify these underlying possibilities, although  the 
TCGA data also allow to identify genotype – phenotype correlations. 
 
The strength of this study  was that in archived clinical FFPE  glioblastoma samples by using 
methods  easily available in routine histopathological labs we were able to identify the 
principal molecular subtypes of the tumor. This approach allowed us to sort  2/3
rd
 of our 
samples into molecular subgroups that likely overlap with those proposed by the TCGA, 
based on the shared markers. We are in the process of extending the present investigation with 
a prospective study in which clinical data and specimens will be collected in real time, in 
order to reproduce our initial findings, and to better define the biological properties of 
glioblastoma subtypes. The ultimate success of our studies may result in the generation of a 
clinical diagnostic panel to support prognostication and therapeutic decisions.  
 
Modern therapies often target molecules that also play important roles in the molecular 
classification of tumors. Such approaches include a broad technical armamentarium targeting 
cells with the EGFRvIII mutant, and include vaccination and antibody therapies. Although no 
breakthrough has been achieved with these modalities, it is highly likely that improved 
survival may result from some of these approaches in the near future for patients in the 
"classic" subgroup with EGFRvIII mutation.  Another new therapeutic approach based on 
biotechnological engineering includes the CAR T cells. These cytotoxic T cells express 
chimeric antigen receptors with arbitrary specificity, which are capable of recognizing a 
selected antigen, e.g. EGFRvIII, and thus to eliminate the expressing glioblastoma cells.  
The identification of the IDH-1 mutants as therapeutic targets goes back to the last decades, 
and successful testing of effective IDH-based therapies has been achieved in experimental 
systems, but none of these approaches could proceed as yet from the preclinical to a clinical 
phase.  Replacement or correction of the expression and function of the tumor suppressor 
molecule, NF-1 could be central to the treatment strategies in several cancers, including 
glioblastoma. Unfortunately, no such treatment has been successfully developed as yet.  It is, 
however, very likely that targeting not only the marker molecules, but also the associated 
mutated molecules, as well as their combinations, by a new generation of inventive 
therapeutic modalities will bring success in the treatment of glioblastomas. The currently 
available research data altogether suggest that an increasingly deepening molecular profiling 
of glioblastomas in the clinical setting will play important roles in the elimination of this very 
malignant and aggressive tumor in the near future.  
6. New scientific results 
  
1. Using methodologies (IHC) available in routine pathology labs and testing clinical FFPE tumor 
specimens, we have examined and reproduced the molecular subgroups of glioblastoma that 
were originally defined by using OMICS methodologies in frozen tumor specimens by the 
TCGA.               
2. We correlated the IHC marker-defined molecular subgroups  with the patients’ clinical 
data.              
3. We refined further the molecular classification of gliomas most recently recommended by the 
WHO, as our analyses demonstrated that determination of the EGFRvIII mutation and the 
NF-1 expression status have clinical relevance in addition to the determination of the  IDH-1 
mutation status.              
4. Confirmation of our observations in a prospective cohort is in progress.  If the conclusions of the 
first study can be proven,  development of a clinico-pathological algorithm is expected for 
patients with glioblastoma to predict prognosis and to support targeted therapies.              
      
5. We have recognized that recurring tumors - even in this small study cohort - largely retain their 
initial molecular profiles despite some signs of clonal evolution ,.              
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Publications in Hungarian 
Nagy Ádám MSc, Éder Katalin, PhD, Kálmán Bernadette, MD, PhD, DSc, FAAN: Characteristics of 
the immune response and possibilities for immune therapy in glioblastoma. HEALTH 
ACADEMY 7: (1) pp. 44-60. (2016)     
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The abstract of the thesis in Hungarian 
Nagy Ádám, MSc, Garzuly Ferenc, MD, PhD, Padányi Gergely, MD, Szűcs Iván, MD, Kalman 
Bernadette, MD, PhD, DSc, FAAN: Determination  molecular subgroups of glioblastoma: -
 In: Carpenter K, Bódog M, Mechler M, Meszaros O (eds.) Book of 
Abstracts. Interdisciplinary Doctoral Conference - Absztraktkötet. Interdisciplinary 
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Table 8. Summary scientometric table 
  
Prepared based on the MTMT publication and citation lists  
Types of publications number 
The number 
of 
independent 
citations 
I. Scientific journal article 2 (4) 7 
Full article, in international 
journals (foreign language) 
1 (2) 7 
Full article in Hungarian 1 (2) - 
II. Book - - 
Scientific book / edited book - - 
Scientific book edited books, 
foreign language 
- - 
Scientific book/ Edited book, 
Hungarian language 
- - 
III. book chapter - - 
a) Professional Book / Book - - 
Book chapter in a foreign 
language 
- - 
Book chapter in Hungarian - - 
Proceedings * 4 - 
In foreign language - - 
In Hungarian 4 - 
Total Publications (I-IV). 6 (8) 7 
Other scientific works ** 14 - 
Total impact factor 2561   
Number of citations   ? 
Hirsch index ?   
  
Notes: 
* Presentation at conferences in journals or book, without abstract.  
** Incomplete publication in scientific journal or publication in journal with unknown 
reviewer evaluation.  
 
